Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
EV-to-EBITDA is calculated as enterprise value divided by its EBITDA. As of today, Mochida Pharmaceutical Co's enterprise value is €520.0 Mil.
Mochida Pharmaceutical Co's EBITDA for the trailing twelve months (TTM) ended in Mar. 2026 was €90.1 Mil. Therefore, Mochida Pharmaceutical Co's EV-to-EBITDA for today is 5.77.
The historical rank and industry rank for Mochida Pharmaceutical Co's EV-to-EBITDA or its related term are showing as below:
FRA:MFY'
s EV-to-EBITDA Range Over the Past 10 Years
Min: 3.65 Med: 8.56 Max: 20.74
Current: 5.91
During the past 13 years, the highest EV-to-EBITDA of Mochida Pharmaceutical Co was 20.74. The lowest was 3.65. And the median was 8.56.
FRA:MFY's EV-to-EBITDA is ranked better than 80.51% of 739
companies
in the Drug Manufacturers industry
Industry Median: 13.2
vs FRA:MFY: 5.91
EV-to-EBITDA is a valuation multiple used in finance and investment to measure the value of a company. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio to determine the fair market value of a company.
Mochida Pharmaceutical Co (FRA:MFY) EV-to-EBITDA Explanation
EV-to-EBITDA is a valuation multiple used in finance and investment to measure the value of a company. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio (TTM) to determine the fair market value of a company.
Mochida Pharmaceutical Co's PE Ratio (TTM) for today is calculated as:
Mochida Pharmaceutical Co's share price for today is €17.30.
Mochida Pharmaceutical Co's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Mar. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was €1.428.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Study has found that the companies with the lowest EV-to-EBITDA outperforms companies measured as cheap by other ratios such as PE Ratio (TTM).
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Drug Manufacturers - Specialty & Generic subindustry, Mochida Pharmaceutical Co's EV-to-EBITDA, along with its competitors' market caps and EV-to-EBITDA data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Mochida Pharmaceutical Co EV-to-EBITDA vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, Mochida Pharmaceutical Co's EV-to-EBITDA distribution charts can be found below:
* The bar in red indicates where Mochida Pharmaceutical Co's EV-to-EBITDA falls into.
Mochida Pharmaceutical Co's current Enterprise Value is €520.0 Mil.
Mochida Pharmaceutical Co's EBITDA for the trailing twelve months (TTM) ended in Mar. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was €90.1 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Mochida Pharmaceutical Co (FRA:MFY) has a EV-to-EBITDA of 5.77 as of Aug. 24, 2026. EV to EBITDA ratio is the company's enterprise value divided by earnings before interest, taxes, depreciation and amortization. View historical data on Mochida Pharmaceutical Co. This is 33% below median its historical median of 8.56. Over the past decade, Mochida Pharmaceutical Co's EV-to-EBITDA has ranged from 3.65 to 20.74. According to the industry distribution chart, Mochida Pharmaceutical Co ranks #144 out of 739 companies in the Drug Manufacturers industry, placing it in the top 19.5%.
Is Mochida Pharmaceutical Co's EV-to-EBITDA too high?
Mochida Pharmaceutical Co's current EV-to-EBITDA of 5.77 is 33% below median its 10-year median of 8.56. Over the past 10 years, this metric has ranged from a low of 3.65 to a high of 20.74. The Drug Manufacturers industry median EV-to-EBITDA is 13.20. Mochida Pharmaceutical Co's value of 5.77 is 56.3% below this industry median. Based on the distribution chart, Mochida Pharmaceutical Co ranks #144 out of 739 companies in the Drug Manufacturers industry, which is in the top quartile — a strong position relative to peers. Overall, Mochida Pharmaceutical Co has a GF Score™ of 64/100, reflecting its overall financial health beyond just this single metric.
How does Mochida Pharmaceutical Co's EV-to-EBITDA compare to ZTS?
According to the Drug Manufacturers industry distribution chart, Mochida Pharmaceutical Co ranks #144 out of 739 companies for EV-to-EBITDA. This places Mochida Pharmaceutical Co in the top 20% of its industry — outperforming the majority of peers. The industry median EV-to-EBITDA is 13.20. Mochida Pharmaceutical Co's value of 5.77 is 56.3% below this benchmark. Historically, Mochida Pharmaceutical Co's own EV-to-EBITDA has ranged from 3.65 to 20.74 over the past decade. While the company's 10-year median is 8.56 vs. the industry median of 13.20, Mochida Pharmaceutical Co has consistently been below the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EV-to-EBITDA for a Drug Manufacturers company?
The median EV-to-EBITDA among Drug Manufacturers companies is 13.20, based on 739 companies in the industry. Companies in the top quartile (top 25%) have a EV-to-EBITDA significantly above this median, while those in the bottom quartile fall well below. However, EV-to-EBITDA should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Mochida Pharmaceutical Co's current EV-to-EBITDA of 5.77 is 56.3% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EV-to-EBITDA mean?
A high EV-to-EBITDA can signal that a stock is expensive relative to its fundamentals. EV to EBITDA ratio is the company's enterprise value divided by earnings before interest, taxes, depreciation and amortization. View historical data on Mochida Pharmaceutical Co. For the Drug Manufacturers industry, the median EV-to-EBITDA is 13.20 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Mochida Pharmaceutical Co's current EV-to-EBITDA is 5.77, which is 33% below median its own 10-year median of 8.56. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Mochida Pharmaceutical Co stock overvalued right now?
Mochida Pharmaceutical Co (FRA:MFY) has a current EV-to-EBITDA of 5.77. The stock's GF Value™ is €19.31, compared to a current price of €17.30 — trading 10.4% below its estimated fair value. The current EV-to-EBITDA is 5.77, which is 33% below median its 10-year median of 8.56 and 56.3% below the Drug Manufacturers industry median of 13.20. Mochida Pharmaceutical Co's overall GF Score™ is 64/100 with 4 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EV-to-EBITDA calculated?
EV-to-EBITDA is calculated from a company's financial statements. For Mochida Pharmaceutical Co (FRA:MFY), the current EV-to-EBITDA is 5.77 as of Aug. 24, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Mochida Pharmaceutical Co (FRA:MFY) Overvalued in 2026?
Based on GuruFocus' analysis, Mochida Pharmaceutical Co stock appears to be undervalued.
The current stock price of €17.30 is trading 10.4% below its estimated GF Value™ of €19.31.
Key valuation signals for FRA:MFY:
EV-to-EBITDA: 5.77 (33% below median its 10-year median of 8.56)
GF Value™: €19.31 vs. price of €17.30 (10.4% below fair value)
Industry Position: 56.3% below the Drug Manufacturers median (#144 of 739)
No single metric tells the full story. See the FRA:MFY stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Mochida Pharmaceutical Co Ltd is a major drug manufacturing company that operates in the field of medical care through its pharmaceuticals, healthcare products, and medical equipment businesses. The company's pharmaceuticals business aims to develop and market a broad spectrum of innovative new drugs. One of Mochida's main objectives is to maximize the business performance of its drugs after they are developed and released. The company also creates skin care products for the general public, and these are supplied through pharmacies, drugstores, and mail-order sales.
64GF Score
Get the complete analysis for FRA:MFY
EV-to-EBITDA is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
FRA:MFY has been successfully added to your 
